503 related articles for article (PubMed ID: 11042698)
1. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R
Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828
[TBL] [Abstract][Full Text] [Related]
4. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations.
Delia D; Goi K; Mizutani S; Yamada T; Aiello A; Fontanella E; Lamorte G; Iwata S; Ishioka C; Krajewski S; Reed JC; Pierotti MA
Oncogene; 1997 May; 14(18):2137-47. PubMed ID: 9174049
[TBL] [Abstract][Full Text] [Related]
5. p53-induced apoptosis in the human T-ALL cell line CCRF-CEM.
Geley S; Hartmann BL; Hattmannstorfer R; Löffler M; Ausserlechner MJ; Bernhard D; Sgonc R; Strasser-Wozak EM; Ebner M; Auer B; Kofler R
Oncogene; 1997 Nov; 15(20):2429-37. PubMed ID: 9395239
[TBL] [Abstract][Full Text] [Related]
6. Endogenous p53 regulation and function in early stage Friend virus-induced tumor progression differs from that following DNA damage.
Kelley LL; Hicks GG; Hsieh FF; Prasher JM; Green WF; Miller MD; Eide EJ; Ruley HE
Oncogene; 1998 Sep; 17(9):1119-30. PubMed ID: 9764822
[TBL] [Abstract][Full Text] [Related]
7. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.
Kotchetkov R; Driever PH; Cinatl J; Michaelis M; Karaskova J; Blaheta R; Squire JA; Von Deimling A; Moog J; Cinatl J
Int J Oncol; 2005 Oct; 27(4):1029-37. PubMed ID: 16142320
[TBL] [Abstract][Full Text] [Related]
8. The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine.
Fan M; Goodwin ME; Birrer MJ; Chambers TC
Cancer Res; 2001 Jun; 61(11):4450-8. PubMed ID: 11389075
[TBL] [Abstract][Full Text] [Related]
9. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
[TBL] [Abstract][Full Text] [Related]
10. p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer.
Bergqvist M; Brattström D; Gullbo J; Hesselius P; Brodin O; Wagenius G
Anticancer Res; 2003; 23(2B):1207-12. PubMed ID: 12820372
[TBL] [Abstract][Full Text] [Related]
11. [Reversing effect of brassinolide on multidrug resistance of-CCRF-VCR1000 cells and a preliminary investigation on its mechanisms].
Xian LJ; Li YQ; Liu RY; Cao QY; Sun J
Yao Xue Xue Bao; 2005 Feb; 40(2):117-21. PubMed ID: 15875665
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 protein expression interferes with p53-independent apoptotic pathways.
Li R; Sutphin PD; Schwartz D; Matas D; Almog N; Wolkowicz R; Goldfinger N; Pei H; Prokocimer M; Rotter V
Oncogene; 1998 Jun; 16(25):3269-77. PubMed ID: 9681825
[TBL] [Abstract][Full Text] [Related]
14. Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities.
Majlessipour F; Kwock R; Martin-Aragon S; Weinberg KI; Avramis VI
Anticancer Res; 2001; 21(1A):11-22. PubMed ID: 11299723
[TBL] [Abstract][Full Text] [Related]
15. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles.
Rand A; Glenn KS; Alvares CP; White MB; Thibodeau SM; Karnes WE
Cancer Lett; 1996 Jan; 98(2):183-91. PubMed ID: 8556707
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity.
Galmarini CM; Falette N; Tabone E; Levrat C; Britten R; Voorzanger-Rousselot N; Roesch-Gateau O; Vanier-Viornery A; Puisieux A; Dumontet C
Br J Cancer; 2001 Sep; 85(6):902-8. PubMed ID: 11556844
[TBL] [Abstract][Full Text] [Related]
17. [Roles of p53 in adriamycin-induced cell death and in acquisition of adriamycin resistance in adult T-cell leukemia (ATL) cells].
Cho Y
Hokkaido Igaku Zasshi; 1999 May; 74(3):239-48. PubMed ID: 10422567
[TBL] [Abstract][Full Text] [Related]
18. Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line.
Geyp M; Ireland CM; Pittman SM
Leukemia; 1996 Mar; 10(3):447-55. PubMed ID: 8642860
[TBL] [Abstract][Full Text] [Related]
19. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.
Satyamoorthy K; Chehab NH; Waterman MJ; Lien MC; El-Deiry WS; Herlyn M; Halazonetis TD
Cell Growth Differ; 2000 Sep; 11(9):467-74. PubMed ID: 11007451
[TBL] [Abstract][Full Text] [Related]
20. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
